Singapore, June 23 -- Sartorius and LFB Biomanufacturing have announced an expansion of their collaboration with the aim of offering biopharmaceutical clients a comprehensive cell-line development (CLD) to first batch of GMP drug substance service.

The collaboration is designed to simplify and accelerate the path to the clinic. Building on their successful collaboration launched in March 2024, this step will combine Sartorius expertise in CLD and master cell bank manufacturing with capabilities from LFB Biomanufacturing, including upstream and downstream process development, analytical development and testing, and GMP drug substance manufacturing.

Together, the collaboration enables Sartorius and LFB Biomanufacturing to gain access to e...